Edimer Pharmaceuticals Competitors

We are a pediatric rare disease pharmaceutical development company. Asklepion Pharmaceuticals, LLC focuses on the discovery, development, and commercialization of pharmaceutical products for pediatric patients with few therapeutic options, due to the rarity of their conditions. Our pipeline currently focuses on rare and critical diseases in children. We strive to channel science and biotechnology into life-saving therapies, and are dedicated to significantly improving the quality of life for sick children and their families. We commit ourselves to high ethical standards, scientific rigor, consistency, and accessibility, so that we can begin to build a better future for children who need our help. Asklepion Pharmaceuticals is comprised of a small group of professionals based in Baltimore, Maryland. We actively engage in partnerships with universities, pharmaceutical companies, distributors, and financial assistance programs to build a firm foundation for FDA product approval and commercialization.

Afecta Pharmaceuticals is an early clinical stage small molecule therapeutics company focused on developing precision medicines to treat chronic disorders and cancers more effectively. Afecta has a validated, proprietary Artificial Intelligence disease/drug targeting platform, PharmetRx®, to discover and optimize Multi-Target drug compounds and formulate them in NanoRx®, our tissue-specific drug delivery technology. Backed by an experienced management team, Afecta is currently advancing AFX-220, our clinically proven lead candidate that effectively treats the disruptive behaviors that occur in children and adolescents with several neurodevelopmental disorders such as Autism, AD/HD, and others. Please visit our website to learn more, register to access our Executive Summary, and receive our latest updates.

A pioneer in immuno-modulation by cell specific delivery of oligonucleotide drugs to antigen presenting cells completing IND enabling studies for a groundbreaking anti-GVHD drug for hematopoietic stem cell transplantation in hematological cancers.